Late onset hypogonadism is defined as clinical and biochemical syndrome characterized by older age, set of typical symptoms, and deficiency in serum testosterone levels.
The quality of life may be decreased and multiple organ systems may be adversely affected.
Prior to the start of testosterone substitution, there should be confirmation of low serum testosterone and a confirmation of need based on clinical findings.
Only if the potential benefit exceeds the risk, then replacement testosterone should be started.
Long-term testosterone therapy in obese men with hypogonadism led to sustained weight loss and improvements in multiple anthropometric parameters, according to an observational study presented at ENDO 2019.
Hypogonadal men with type 2 diabetes are highly likely to have higher bone mass density (BMD), poorer bone geometry and relatively suppressed bone turnover compared with their nondiabetic counterparts, a study has shown.
Treatment with testosterone solution 2 percent (T-sol) for 6 months was generally well tolerated and did not show new safety concerns, according to a study. In addition, the outcomes of low sex drive and low energy indicated further improvement after the double-blind phase.
Testosterone replacement therapy (TRT) in hypogonadal men was associated with a lower cardiovascular (CV) risk, according to a presentation at the recent Urological Association of Asia Annual Congress (UAA 2016) held in Singapore, allaying concerns about the safety of TRT amidst controversial findings from previous studies.